{"id":"jt001","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital yeast infections"}]},"_chembl":{"chemblId":"CHEMBL5219660","moleculeType":"Small molecule","molecularWeight":"402.48"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, JT001 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.","oneSentence":"JT001 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:17:38.980Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT05802810","phase":"PHASE1","title":"The Mass Balance Study of [14C]JT001","status":"COMPLETED","sponsor":"Shanghai Vinnerna Biosciences Co., Ltd.","startDate":"2023-03-18","conditions":"Healthy Subjects","enrollment":7},{"nctId":"NCT06142201","phase":"","title":"A Real-World Study of JT001 for COVID-19","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Vinnerna Biosciences Co., Ltd.","startDate":"2023-08-31","conditions":"COVID-19","enrollment":7656},{"nctId":"NCT06165965","phase":"PHASE1","title":"To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JT-001, JT-002 and JLP-2008","status":"COMPLETED","sponsor":"Jeil Pharmaceutical Co., Ltd.","startDate":"2022-05-03","conditions":"Healthy Adult","enrollment":48},{"nctId":"NCT06093308","phase":"PHASE1","title":"A Study in Elderly Chinese Subjects With Underlying Diseases","status":"COMPLETED","sponsor":"Shanghai Vinnerna Biosciences Co., Ltd.","startDate":"2023-07-12","conditions":"Elderly Subjects With Underlying Diseases","enrollment":18},{"nctId":"NCT06093230","phase":"PHASE1","title":"A Study in Subjects With Liver Function Injury and Subjects With Normal Liver Function","status":"COMPLETED","sponsor":"Shanghai Vinnerna Biosciences Co., Ltd.","startDate":"2023-07-28","conditions":"Subjects With Liver Function Injury, Normal Liver Function Subject","enrollment":24},{"nctId":"NCT05895812","phase":"PHASE1","title":"A Study in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function","status":"COMPLETED","sponsor":"Shanghai Vinnerna Biosciences Co., Ltd.","startDate":"2023-05-08","conditions":"Subjects With Renal Impairment, Healthy Subjects","enrollment":24},{"nctId":"NCT05242042","phase":"PHASE2, PHASE3","title":"JT001 (VV116) for the Early Treatment of COVID-19","status":"TERMINATED","sponsor":"Shanghai JunTop Biosciences Co., LTD","startDate":"2022-01-28","conditions":"Mild to Moderate COVID-19","enrollment":381},{"nctId":"NCT05582629","phase":"PHASE3","title":"JT001 (VV116) for the Treatment of COVID-19","status":"COMPLETED","sponsor":"Shanghai Vinnerna Biosciences Co., Ltd.","startDate":"2022-10-21","conditions":"Mild to Moderate COVID-19","enrollment":1369},{"nctId":"NCT05355077","phase":"PHASE1","title":"Evaluate the Pharmacokinetics, Safety and Tolerability of JT001 Tablets","status":"WITHDRAWN","sponsor":"Shanghai Vinnerna Biosciences Co., Ltd.","startDate":"2022-05-02","conditions":"Healthy Subjects","enrollment":""},{"nctId":"NCT05279235","phase":"PHASE3","title":"Efficacy and Safety of JT001 (VV116) Compared With Favipiravir","status":"TERMINATED","sponsor":"Shanghai Vinnerna Biosciences Co., Ltd.","startDate":"2022-03-14","conditions":"Moderate to Severe COVID-19","enrollment":290},{"nctId":"NCT05341609","phase":"PHASE3","title":"Efficacy and Safety of JT001 (VV116) Compared With Paxlovid","status":"COMPLETED","sponsor":"Vigonvita Life Sciences","startDate":"2022-04-04","conditions":"COVID-19","enrollment":822},{"nctId":"NCT05101135","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of JT-001 add-on in Paatients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin","status":"UNKNOWN","sponsor":"Jeil Pharmaceutical Co., Ltd.","startDate":"2021-11-17","conditions":"Type 2 Diabetes Mellitus","enrollment":256}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["VV116","VV116 placebo","DeuremidevirHydrobromideTablets"],"phase":"phase_3","status":"active","brandName":"JT001","genericName":"JT001","companyName":"Shanghai Vinnerna Biosciences Co., Ltd.","companyId":"shanghai-vinnerna-biosciences-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"JT001 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}